According to The Insight Partners' research, the Europe Knee Implants Market was valued at US$ 3,195.9 Million in 2024 and is expected to reach US$ 4,603.6 Million by 2031, registering a CAGR of 5.4% from 2025 to 2031.
Adoption of cement-sensitive implant alternatives and elective backlog and increased waiting times reshaping surgeries are among the critical factors attributed to drive the Europe knee implants market growth.
Increasing regulatory approvals for cementless implants and those tailored for patients with sensitivities to metals or bone cement are unlocking new opportunities in the knee implant market. According to official FDA data, in December 2024, Zimmer Biomet received 510(k) clearance for its Persona SoluTion PPS Femur, a total knee implant component designed for cementless fixation and reduced exposure to common metal sensitizers, such as nickel, cobalt, and chromium. These product innovations address concerns about implant longevity, immune reactions, and revision surgery. The addressable patient pool can expand with increasing aging populations, who may have compromised bone quality or metal sensitivities. Furthermore, long-term outcomes in registries support strong survival rates: e.g., the Oxford Cementless Partial Knee shows ~94.1% survival at 10 years in UK National Joint Registry data, higher than many cemented counterparts. Thus, manufacturers who invest in materials science, surface engineering, and implant design for cementless fixation or metal-agnostic materials are likely to gain a competitive advantage as demand for these types of implants increases.
On the contrary, the long waiting times and access delays in public health systems hamper the growth of the Europe knee implants market.
Europe Knee Implants Market Segmentation Analysis:
- By Type of Procedures, the Europe Knee Implants Market is segmented into Total Knee Replacement, Partial Knee Replacement, and Revision Knee Replacement. The Total Knee Replacement segment is projected to expand at a CAGR of 5.3% during 2025 - 2031.
- By Implant Type, the Europe Knee Implants Market is segmented into Fixed Bearing Prosthesis and Mobile Bearing Prosthesis. The Fixed Bearing Prosthesis segment is projected to expand at a CAGR of 5.8% during 2025 - 2031.
- By Material, the Europe Knee Implants Market is segmented into Cemented and Non-Cemented. The Cemented segment is projected to expand at a CAGR of 5.8% during 2025 - 2031.
- By End User, the Europe Knee Implants Market is segmented into Hospitals, Orthopedic Clinics, Others, and Ambulatory Surgical Centers. The Hospitals segment is projected to expand at a CAGR of 5.9% during 2025 - 2031.
By country, the Europe Knee Implants Market is categorized into Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe. Germany is projected to expand at a CAGR of 7.3% during 2025 - 2031.
Key players operating in the Knee Implants Market are MicroPort Scientific Corp, Medtronic Plc, Stryker Corp, Zimmer Biomet Holdings Inc, Smith & Nephew Plc, Conmed Corp, Exactech Inc, B. Braun Melsungen AG, Enovis Corp, and Medacta Group SA, among others.
- In March 2025, Stryker showcased the latest advancements in Mako SmartRobotics for hip, knee, spine, and shoulder procedures at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally in 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Revision, Stryker expanded on its established Mako Total Hip offering to include a first-to-market robotic hip revision capability. In revision total hip arthroplasty (THA), the expanded Mako Total Hip application is engineered to streamline workflow and enable confidence in challenging procedures with new features such as augment and screw planning, intraoperative screw trajectory guidance and compatibility with Stryker's revision hip implant portfolio. These new capabilities are designed to help surgeons simplify hip procedures by knowing more with Mako's 3D CT-based planning, now across both primary and revision THA procedures.
- In December 2023, Exactech Inc. announced that its subsidiary, BlueOrtho, has received 510(k) clearance from the Food and Drug Administration for ExactechGPS® Ankle, the world's first surgical navigation system for total ankle arthroplasty (TAA).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com